Larimar Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Bala cynwyd, pa., march 14, 2024 (globe newswire) -- larimar therapeutics, inc. (“larimar”) (nasdaq: lrmr), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.

Bala cynwyd, pa., march 11, 2024 (globe newswire) -- larimar therapeutics, inc. (“larimar”) (nasdaq: lrmr), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced dosing of the first patient in an open label extension (ole) study evaluating 25 mg daily subcutaneous injections of nomlabofusp in participants with friedreich's ataxia (fa). nomlabofusp (cti-1601) is a novel protein replacement therapy designed to address the root cause of friedreich's ataxia (fa) by delivering frataxin to mitochondria.

Bala cynwyd, pa., march 06, 2024 (globe newswire) -- larimar therapeutics, inc. (“larimar”) (nasdaq: lrmr), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the leerink partners global biopharma conference, taking place in miami beach, fl from march 11 – 13, 2024.

Bala cynwyd, pa., feb. 16, 2024 (globe newswire) -- larimar therapeutics, inc. (“larimar”) (nasdaq: lrmr), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on february 13, 2024. the aggregate gross proceeds to larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172...

Bala cynwyd, pa., feb. 14, 2024 (globe newswire) -- larimar therapeutics, inc. (“larimar”) (nasdaq: lrmr), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 17,162,472 shares of its common stock at a price to the public of $8.74 per share, the closing price of its common stock on february 13, 2024, for gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. in addition, larimar has granted the underwriters a 30-day option to purchase up to an additional 2,574,370 shares of its common stock at the public offering price, less underwriting discounts and commissions...

BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference, taking place in Miami Beach, FL from March 11 – 13, 2024.

BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023.

Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort expected 1st half of 2024. Clearance given to initiate open-label extension study of CTI-1601 for Friedreich's Ataxia; study initiation Q1 of 2024 and then interim results Q4 of 2024. Prior phase 1 study, using CTI-1601 for the treatment of patients with Friedreich's Ataxia, showed that the drug was able to increase frataxin levels in a dose-dependent manner.

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company's presentation will take place on Thursday, December 1, 2022, at 10:10 AM ET.

Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

PBR, HP, MNTK, LRMR and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2022.